Sugi Predict

Sugi Predict / Compounds / SCHEMBL23498013

SCHEMBL23498013

SCHEMBL23498013

CC(C)[C@H](NC(=O)CCOCCOCCOCCN=[N+]=[N-])C(=O)N[C@@H](CCCNC(N)=O)C(=O)Nc1ccc(COC(=O)Oc2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 1/20 0.39
▸ FURIN P09958 10/20 0.37
▸ MAP1LC3B Q9GZQ8 2/20 0.36
▸ SSTR3 P32745 1/20 0.35
▸ PDF Q9HBH1 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ FOLH1 Q04609 1/20 0.34
▸ TGM2 P21980 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17490581 1.00 HTR2A (0.39) HTR2AFURINMAP1LC3BSSTR3PDF
SCHEMBL23498015 1.00 HTR2A (0.39) HTR2AFURINMAP1LC3BSSTR3PDF
SCHEMBL25976125 0.99 HTR2A (0.39) HTR2AFURINMAP1LC3BSSTR3PDF
SCHEMBL19731615 0.95 FURIN (0.39) HTR2AFURINMAP1LC3BSSTR3PDF
SCHEMBL22691442 0.95 FURIN (0.39) HTR2AFURINMAP1LC3BSSTR3PDF
SCHEMBL29649550 0.94 PDF (0.38) FURINSSTR3PDFFOLH1
SCHEMBL15223879 0.93 HTR2A (0.39) HTR2AFURINMAP1LC3BSSTR3PDF
SCHEMBL18792771 0.93 HTR2A (0.39) HTR2AFURINMAP1LC3BSSTR3PDF
SCHEMBL17312903 0.92 HTR2A (0.40) HTR2AFURINMAP1LC3BSSTR3PDF
SCHEMBL26015668 0.92 HTR2A (0.40) HTR2AFURINMAP1LC3BSSTR3PDF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4073062-B1 FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) RYVU THERAPEUTICS S A (PL) 2026-04-29 — — EP disclosed
EP-4727586-A1 ANTI-CD5 ANTIBODIES AND THEIR USES Synthis Therapeutics, Inc. (US) 2026-04-22 — — EP disclosed
US-20260053939-A1 Combination Therapy for Cancer GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-02-26 — — US disclosed
WO-2025242908-A2 NOVEL COMPOUNDS GENOME THERAPEUTICS LTD (GB) 2025-11-27 — — WO disclosed
WO-2025133338-A1 QUINOLONE DERIVATVES AGAINST CANCER GENOME THERAPEUTICS LTD (GB) 2025-06-26 — — WO disclosed
WO-2025125302-A1 NOVEL COMPOUNDS GENOME THERAPEUTICS LTD (GB) 2025-06-19 — — WO disclosed
US-20250114441-A1 POLYMERIC VACCINE FOR OPIOID ADDICTION THE JOHNS HOPKINS UNVERSITY 2025-04-10 — — US disclosed
WO-2024258967-A1 ANTI-CD5 ANTIBODIES AND THEIR USES SYNTHIS THERAPEUTICS, INC. (US) 2024-12-19 — — WO disclosed
EP-4469484-A1 COMBINATION THERAPY FOR CANCER GlaxoSmithKline Intellectual Property Development Ltd (GB) 2024-12-04 — — EP disclosed
WO-2024190929-A1 PH-RESPONSIVE CARRIER FOR PROTEIN DELIVERY 国立大学法人 東京大学 2024-09-19 — — WO disclosed
WO-2023159176-A1 COMBINATION THERAPY FOR B-CELL DISORDERS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-08-24 — — WO disclosed
WO-2023144702-A1 COMBINATION THERAPY FOR CANCER GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-08-03 — — WO disclosed
US-20230090552-A1 ALK5 INHIBITOR CONJUGATES AND USES THEREOF SYNTHIS THERAPEUTICS, INC. (US) 2023-03-23 — — US disclosed
US-20230055741-A1 FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2023-02-23 — — US disclosed
EP-4073062-A1 FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-10-19 — — EP disclosed
US-20220249680-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS THERAPEUTICS, INC. (US) 2022-08-11 — — US disclosed
WO-2022087156-A1 PROINFLAMMATORY PRODRUGS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-04-28 — — WO disclosed
EP-3986468-A1 ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES Synthis Therapeutics, Inc. (US) 2022-04-27 — — EP disclosed
CN-114269388-A antibody-ALK 5 inhibitor conjugates and uses thereof 辛瑟斯治疗股份有限公司 2022-04-01 — — CN disclosed
WO-2021116446-A1 FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2021-06-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260053939-A1 Combination Therapy for Cancer BCL6, PSMB6, PDCD6 HTR2A 4727/4885FURIN 4825/4885MAP1LC3B 439/4885
US-20220249680-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES ALK, ALKBH5, ALKBH3 HTR2A 3236/4885FURIN 3714/4885MAP1LC3B 1656/4885
US-20230090552-A1 ALK5 INHIBITOR CONJUGATES AND USES THEREOF ALK, ALKBH5, ALKBH3 HTR2A 3518/4885FURIN 3806/4885MAP1LC3B 1573/4885
US-20250114441-A1 POLYMERIC VACCINE FOR OPIOID ADDICTION OPRM1, OPRK1, OPRL1 HTR2A 656/4885FURIN 1748/4885MAP1LC3B 1113/4885
US-20230055741-A1 FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS HTR2A 1451/4885FURIN 1532/4885MAP1LC3B 3195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback